THEMATIC REVIEW

90 YEARS OF PROGESTERONE

Selective progesterone receptor modulators in gynaecological therapies

H O D Critchley and R R Chodankar

MRC Centre for Reproductive Health, The University of Edinburgh, The Queen's Medical Research Institute, Edinburgh Bioquarter, Edinburgh, UK

Correspondence should be addressed to H O D Critchley: Hilary.Critchley@ed.ac.uk

This review forms part of a special section on 90 years of progesterone. The guest editors for this section are Dr Simak Ali, Imperial College London, UK, and Dr Bert W O'Malley, Baylor College of Medicine, USA.

Abstract

Abnormal uterine bleeding (AUB) is a chronic, debilitating and common condition affecting one in four women of reproductive age. Current treatments (conservative, medical and surgical) may be unsuitable, poorly tolerated or may result in loss of fertility. Selective progesterone receptor modulators (SPRMs) influence progesterone-regulated pathways, a hormone critical to female reproductive health and disease; therefore, SPRMs hold great potential in fulfilling an unmet need in managing gynaecological disorders. SPRMs in current clinical use include RU486 (mifepristone), which is licensed for pregnancy interruption, and CDB-2914 (ulipristal acetate), licensed for managing AUB in women with leiomyomas and in a higher dose as an emergency contraceptive. In this article, we explore the clinical journey of SPRMs and the need for further interrogation of this class of drugs with the ultimate goal of improving women's quality of life.

Introduction

Selective Progesterone Receptor Modulators (SPRMs) are a class of synthetic steroids with different molecular structures. They interact with the progesterone receptor (PR) and may exert an agonist, antagonist or a mixed response (Lusher et al. 2011). Progesterone plays a vital role in the structure, function and regulation of the female reproductive tract, including pregnancy. Progesterone mediates its function by interacting with the PR, a member of a superfamily of almost 50 ligand-activated nuclear transcription factors (McEwan 2009).

A large number of gynaecological problems such as abnormal uterine bleeding (AUB), fibroids (leiomyoma), adenomyosis, endometriosis and reproductive tract cancers are hormonally mediated; therefore, SPRMs hold great potential for the management of women with gynaecological disorders.

History of SPRMs

The search for drugs that modify progesterone activity with an aim to achieve contraception can be traced back to the 1960s (Pincus 1960). The first SPRM, RU486 (mifepristone), was discovered in the 1980s, during the quest for discovery for anti-glucocorticoid drugs (Moguilewsky & Philibert 1984).

Several SPRMs have been developed (Fig. 1) since, and the latest in this class of drugs is vilaprisan. The development of SPRMS is shown in the timeline in Fig. 1.
Non-steroidal SPRMs aim to achieve the effect of progesterone receptor binding that can selectively act as a progestin in the endometrium while acting as an antiprogestin within the leiomyoma; however, there is a limited clinical translation of these agents (Catherino et al. 2010).

Clinical need for SPRMs

Heavy Menstrual Bleeding (HMB) affects one in four women of reproductive age. It accounts for over a million annual referrals to the gynaecology services in the United Kingdom (UK) (Shapley et al. 2004, Royal College of Obstetricians and Gynaecologists 2014). The effects of HMB may be so profound that the National Institute for Clinical Excellence (NICE 2018) defines HMB as any bleeding that negatively impacts the woman’s physical, emotional, social and/or material quality of life (NICE 2018). This definition steers us away from the traditional definition (now only used in a research context – menstrual blood loss over 80 mL/cycle) of quantitatively estimating blood loss to define HMB (Hallberg & Nilsson 1964, Warner et al. 2004).

HMB is also associated with economic implications for the healthcare system and loss of productivity due to time off work and presenteeism. Medical treatments may be ineffective, unsuitable or have undesirable side effects for some women. Surgical treatments for HMB may be invasive and may have associated surgical and anaesthetic risks and may cause a permanent loss of fertility for women (Frick et al. 2009).

A recent review using the data derived from the National HMB Audit (England and Wales) included nearly 15,000 women. The data showed that 54% of women seeking HMB treatment were under 45 years, with approximately two-thirds having no other co-morbidity. Half of the women under 45 years received fertility-ending surgery (hysterectomy or endometrial ablation) in the first year of referral to secondary services (Geary et al. 2019). However, given over half of all UK-born babies (55%) are to women aged 30 or older, fertility-ending surgery is not always acceptable (Office for National Statistics 2017). A recent Dutch study based on an internet survey of nearly 43,000 women suggested that because of menstrual symptoms, nearly 38% of women reported being unable to perform their regular daily activities (Schoep et al. 2019).
2019). There remains an unmet clinical need in managing women with HMB.

The role of SPRMs in emergency contraception is well established. Further exploration is ongoing to investigate the role of SPRMs as an oestrogen-free method of long-term contraception.

This article focuses on the SPRMs in current clinical use or undergoing investigation in clinical trials (Fig. 1).

**Ulipristal acetate (UPA or CDB-2914 or VA-2914)**

UPA was first studied in the 1990s in the context of an ‘antifertility’ drug in keeping with the properties of RU486 (mifepristone), both in rats and humans (Passaro et al. 1997, Reel et al. 1998). Like mifepristone, UPA was labelled an ‘antiprogestin’ when initially developed and only in recent years has been classed as an SPRM. UPA is a steroidal SPRM with a structure of a 19 norprogesterone derivative: 17a-Acetoxy-11b-(4-N, N-Dimethylaminophenyl)-19-norpregn-4-9-diene-3,20-dione, also known as CDB 2914, since it was initially developed by the National Institute of Child Health and Human Development (NICHD). It is also known as HRP 2000 or VA 2914 (Bouchard 2014). The chemical structure of UPA is illustrated in Fig. 2.

**Emergency Contraception (EC) Overview (United Kingdom)**

UPA is United States Food and Drug Administration (US FDA) approved as an emergency contraceptive and is licensed in the United Kingdom for this purpose, including for over the counter (OTC) use (European Consortium for Emergency Contraception 2017). Evidence suggests that the most effective emergency contraceptive is a Copper intrauterine device (Cu-IUD). It has a failure rate of <1% when inserted within 5 days (120 h) after the first unprotected sexual intercourse (UPSI) in a natural cycle or within 5 days after the earliest estimated date of ovulation (whichever is later). The Faculty of Sexual and Reproductive Healthcare (FSRH) suggests it has the added advantage of providing ongoing contraception (Cleland et al. 2012, The Faculty of Sexual & Reproductive Healthcare 2017). There are limitations of using an IUD for this purpose; it cannot be used in women with an active pelvic infection, undiagnosed genital tract bleeding or distortion of uterine anatomy. It requires a medical professional available for insertion. Ongoing risks include that of uterine perforation, abnormal uterine bleeding and dysmenorrhoea in some users.

![Chemical structure of UPA.](https://jme.bioscientifica.com/)

Other emergency contraceptive methods licensed in the United Kingdom include oral levonorgestrel (LNG) and oral UPA. LNG is used in a dose of 1.5 mg orally (single dose) and is licensed for use up to 72 h after UPSI or contraceptive failure. UPA is used in a dose of 30 mg and is licensed for up to 120 h for the same indications (The Faculty of Sexual & Reproductive Healthcare 2017). Current evidence suggests that UPA is more effective than LNG as an emergency contraceptive (Glasier et al. 2010, Shen et al. 2019).

The combined hormonal ‘Yuzpe method’ is no longer recommended for use in the United Kingdom, as evidence suggests lower efficacy as compared to LNG EC alone (Cheng et al. 2012, Leung et al. 2016). The oestrogen–progestin regimen comprises two doses of a combination of 100 μg of ethinyl oestradiol and 0.5 mg of levonorgestrel each, the first dose taken within 72 h after intercourse and the second 12 h later (Yuzpe & Lancee 1977, Glasier 1997). There is a current lack of evidence to recommend the LNG-IUS as a method of emergency contraception (The Faculty of Sexual & Reproductive Healthcare 2017).

**UPA and Emergency Contraception (EC)**

The predominant mechanism of action of UPA is inhibition or delay of ovulation by interrupting the luteinising hormone (LH) surge (Stratton et al. 2000). However, even when the LH surge has commenced, UPA can prevent ovulation, suggesting a direct effect on the growing ovarian follicle (Nallasamy et al. 2013).

In addition to inhibition of ovulation, endometrial effects (molecular) of UPA are also proposed, which may impact decidualisation and consequently implantation.
Lira-Albarran et al. 2018). Endometrial effects have also been proposed at a macroscopic level (Stratton et al. 2000, 2010, Passaro et al. 2003). Hence, UPA may be both contraceptive and contragestive in its actions, making it an effective emergency contraceptive (Keenan 2011).

This effect has been questioned in more recent reviews. Authors propose that the endometrial effects seen with UPA use may simply reflect a consequence of a delay in ovulation or require fairly large doses of UPA which are not currently used for UPA-EC (Li et al. 2019).

### UPA and long-term contraception

Given the beneficial effects of UPA as an EC, its role as a long-term contraceptive has been explored in the form of a contraceptive vaginal ring (Jensen 2013). The study suggested that at a dose of 2500 µg/day, ovulation could be suppressed in up to 86% of treatment cycles assessed by transvaginal ultrasound and a hormonal assay. Progesterone receptor modulator associated endometrial changes (PAEC) were seen in nearly 79% of participants; however, PAEC were resolved upon UPA discontinuation (Huang et al. 2014). Further investigation is needed to elucidate the role of UPA as a long-term oestrogen free contraceptive.

### UPA and fibroids (leiomyomases)

UPA is the only SPRM specifically approved and commercialised to date for management of symptomatic uterine fibroids. UPA controls HMB in over 90% of women, with an overall decrease in bleeding similar to gonadotrophin releasing hormone (GnRH) agonist use. It has a faster onset of amenorrhoea, usually within 10 days. Oestradiol levels are maintained in the mid-follicular phase range during treatment, thereby reducing the likelihood of menopausal symptoms. Revised European Medicines Agency (EMA) and Medicines and Healthcare Products Regulatory Agency (MHRA) guidance should be used to guide UPA use (Table 1).

#### Table 1 Current indications and restrictions of use of UPA in the United Kingdom and Europe (adapted from European Medicines Agency 2018, Medicines and Healthcare Products Regulatory Agency 2018).

<table>
<thead>
<tr>
<th>Indications</th>
<th>Liver function monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>UPA is indicated for the intermittent treatment of moderate to severe symptoms of uterine fibroids in women of reproductive age who are not eligible for surgery</td>
<td>Before initiation of each treatment course: perform liver function tests; do not initiate UPA in women with baseline alanine transaminase (ALT) or aspartate aminotransferase (AST) more than twice the upper limit of normal (ULN). During the first two UPA treatment courses: perform liver function tests every month.</td>
</tr>
<tr>
<td>UPA is indicated for one course of preoperative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age</td>
<td>For further treatment courses: perform liver function tests once before each new course and when clinically indicated.</td>
</tr>
<tr>
<td>UPA treatment is to be initiated and supervised by a physician experienced in the diagnosis and treatment of uterine fibroids</td>
<td>At the end of each treatment course: perform liver function tests after 2–4 weeks. Stop UPA treatment and closely monitor women with ALT or AST more than three times the upper limit of normal; consider the need for specialist hepatology referral.</td>
</tr>
<tr>
<td>UPA is contraindicated in women with underlying liver disorders</td>
<td></td>
</tr>
</tbody>
</table>

UPA and liver function

UPA was licensed for use in the UK and EU in 2012 for the management of fibroids related HMB. During post-marketing surveillance of women exposed to UPA (approximately 765,000), eight cases of serious liver injury were identified, and of these cases, four required a liver transplant (https://www.ema.europa.eu/en/documents/variation-report/esmya-h-c-2041-a20-0043-epar-assessment-report-article-20_en.pdf last accessed: 08/08/2018). This meant the use of UPA was temporarily halted for investigation. After considering all the evidence, in May 2018, the Pharmacovigilance Risk Assessment Committee (PRAC) of the EMA concluded that UPA may have contributed to the development of some cases of serious liver injury; however, the status of UPA as a medication responsible for drug-induced liver injury (DILI) was not fully confirmed (European Medicines Agency 2018). UPA was reintroduced with clinical restrictions and liver function monitoring (Table 1).

UPA does not belong to any of the drug classes commonly considered as drug-induced liver injury agents, nor has it any molecular features similar to other drugs in the DILI network (Donnez et al. 2018a). The current understanding is that UPA may be responsible for idiosyncratic (rather than intrinsic) DILI and that the use of liver health monitoring will help to minimise risks associated with its use (Donnez 2018).
From the clinician’s perspective, review of the available clinical trial data suggests there were no cases in the 5 mg once daily (OD) UPA group (approved clinical dose) showing any liver enzymes outside accepted ranges (Donnez 2018, Donnez et al. 2018a).

Abnormalities in liver function tests have also been previously noted with the use of SPRMs including mifepristone and proellex (CDB-4124). All of these compounds have the 4-(dimethylamino) phenyl group in common. This structural element is accessible to metabolic demethylations, which may lead to the formation of aniline metabolites that have been reported to cause undesired effects in the liver by the formation of reactive intermediates (Lu et al. 2015). The data from clinical studies with SPRMs lacking the dimethylamino phenyl group, for example, lonaprisan, have provided no evidence of a clinically relevant, drug-related change in liver enzyme activity (Möller et al. 2018).

### UPA and clinical trials

The majority of the clinical evidence for use for UPA in management of women with heavy menstrual bleeding and fibroids is available from the PGL4001 (ulipristal acetate) Efficacy Assessment in Reduction of symptoms due to uterine Leiomyomata, PEARL (four phase three trials; PEARL I–IV), and Assessment of Endometrial Safety During Treatment of Symptomatic Uterine Fibroids With Ulipristal Acetate, VENUS (I–II) trials (Donnez et al. 2012a,b, 2014, 2015, Illingworth et al. 2018, Simon et al. 2018) (Table 2).

The PEARL trials and VENUS trials differed in that; the PEARL trials were conducted in European Centres with a subset of participants that was predominantly Caucasian and had a strict BMI cut-off. The VENUS trials were conducted in the United States with a predominantly (70%) African American population of participants and no BMI cut-offs. As with the PEARL trials, VENUS trials also supported the meaningful positive impact of UPA on women’s quality of life (Lukes et al. 2019).

Real-world data are also available from an observational study – the A Prospective Multicenter Non-interventional Study of Women Treated With ESMYA (ulipristal acetate) as Preoperative Treatment of Moderate to Severe Symptoms of Uterine Fibroids (PREMYA) study involving 1473 women. Participants in this study received a 3-month course of 5 mg of UPA preoperatively. Only 38.8% of patients underwent surgery, mostly of a conservative/minimally invasive nature, and there were clinically relevant improvements in pain and health-related quality of life (HRQoL) scores (Fernandez et al. 2017).

### UPA and endometrial changes

SPRMs have a progesterone antagonist effect and when used clinically there is a theoretical risk of unopposed endometrial oestrogen exposure and subsequent endometrial hyperplasia or cancer due to progesterone antagonism with use of SPRMs. Progesterone Receptor Modulator Associated Endometrial Changes (PAEC) are a spectrum of morphological endometrial effects seen with SPRM use, that is, representing a class effect with the use of the drugs. PAEC histology characteristically shows cystically dilated glands with non-physiological secretory appearances, inactive epithelium and few mitotic figures, in a background of a compact non-decidualised stroma (Williams et al. 2012) (Fig. 3).

UPA administration has been shown to affect the expression and localisation of endometrial sex steroid receptors, modulate progesterone-responsive genes and to reduce endometrial cell proliferation (Whitaker et al. 2017). There is limited information available on the impact of SPRMs, such as UPA on the human endometrium at the molecular/cellular level.

A recent systematic review has examined the endometrial effects of UPA use in ten studies involving 1450 women. The review supports the current understanding of PAEC; that it is essentially a benign condition, and reversible on discontinuation of UPA use. Most studies, however, have a limited follow-up period and have used UPA in up to four intermittent courses, so further research is needed before assuming that SPRMs including UPA are safe for long-term use (De Milliano et al. 2017).

### UPA and fibroids (morphological changes)

UPA is known to have proapoptotic, antiﬁbrotic and antiproliferative effects on uterine fibroids (Xu et al. 2005, Courtoy et al. 2015, Donnez et al. 2018b). This is significant clinically, as fibroids treated with UPA that have reduced in size do not increase in size immediately after discontinuation of UPA use, unlike after treatment with GnRH agonists, where fibroid growth may recommence as early as 4 weeks following cessation of treatment (Donnez et al. 2012b).

UPA also alters the expression of angiogenic proteins, such as vascular endothelial growth factor, and reduces the amount of extracellular matrix by increasing matrix protein turnover (Fett et al. 2012). The majority of the clinical evidence for use for UPA in management of women with heavy menstrual bleeding and fibroids is available from the PGL4001 (ulipristal acetate) Efficacy Assessment in Reduction of symptoms due to uterine Leiomyomata, PEARL (four phase three trials; PEARL I–IV), and Assessment of Endometrial Safety During Treatment of Symptomatic Uterine Fibroids With Ulipristal Acetate, VENUS (I–II) trials (Donnez et al. 2012a,b, 2014, 2015, Illingworth et al. 2018, Simon et al. 2018) (Table 2).

The PEARL trials and VENUS trials differed in that; the PEARL trials were conducted in European Centres with a subset of participants that was predominantly Caucasian and had a strict BMI cut-off. The VENUS trials were conducted in the United States with a predominantly (70%) African American population of participants and no BMI cut-offs. As with the PEARL trials, VENUS trials also supported the meaningful positive impact of UPA on women’s quality of life (Lukes et al. 2019).

Real-world data are also available from an observational study – the A Prospective Multicenter Non-interventional Study of Women Treated With ESMYA (ulipristal acetate) as Preoperative Treatment of Moderate to Severe Symptoms of Uterine Fibroids (PREMYA) study involving 1473 women. Participants in this study received a 3-month course of 5 mg of UPA preoperatively. Only 38.8% of patients underwent surgery, mostly of a conservative/minimally invasive nature, and there were clinically relevant improvements in pain and health-related quality of life (HRQoL) scores (Fernandez et al. 2017).

### UPA and endometrial changes

SPRMs have a progesterone antagonist effect and when used clinically there is a theoretical risk of unopposed endometrial oestrogen exposure and subsequent endometrial hyperplasia or cancer due to progesterone antagonism with use of SPRMs. Progesterone Receptor Modulator Associated Endometrial Changes (PAEC) are a spectrum of morphological endometrial effects seen with SPRM use, that is, representing a class effect with the use of the drugs. PAEC histology characteristically shows cystically dilated glands with non-physiological secretory appearances, inactive epithelium and few mitotic figures, in a background of a compact non-decidualised stroma (Williams et al. 2012) (Fig. 3).

UPA administration has been shown to affect the expression and localisation of endometrial sex steroid receptors, modulate progesterone-responsive genes and to reduce endometrial cell proliferation (Whitaker et al. 2017). There is limited information available on the impact of SPRMs, such as UPA on the human endometrium at the molecular/cellular level.

A recent systematic review has examined the endometrial effects of UPA use in ten studies involving 1450 women. The review supports the current understanding of PAEC; that it is essentially a benign condition, and reversible on discontinuation of UPA use. Most studies, however, have a limited follow-up period and have used UPA in up to four intermittent courses, so further research is needed before assuming that SPRMs including UPA are safe for long-term use (De Milliano et al. 2017).

### UPA and fibroids (morphological changes)

UPA is known to have proapoptotic, antiﬁbrotic and antiproliferative effects on uterine fibroids (Xu et al. 2005, Courtoy et al. 2015, Donnez et al. 2018b). This is significant clinically, as fibroids treated with UPA that have reduced in size do not increase in size immediately after discontinuation of UPA use, unlike after treatment with GnRH agonists, where fibroid growth may recommence as early as 4 weeks following cessation of treatment (Donnez et al. 2012b).

UPA also alters the expression of angiogenic proteins, such as vascular endothelial growth factor, and reduces the amount of extracellular matrix by increasing matrix protein turnover (Fett et al. 2012).
<table>
<thead>
<tr>
<th>Study</th>
<th>Type</th>
<th>Population</th>
<th>Intervention and comparator</th>
<th>Outcomes</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEARL I</td>
<td>Randomised Double blind Placebo controlled</td>
<td>Women with symptomatic fibroids; Age: 18–50 years; BMI: 18–40 kg/m²; PBAC score &gt;100 (first 8 days of menstruation); At least one uterine fibroid &gt;3 cm but &lt;10 cm; Fibroid uterus: &lt;6 weeks; Anaemia: Hb &lt;10.2 g/dL; Eligible for surgery</td>
<td>Women were randomised in a ratio of 2:2:1 to 5 mg/day UPA (n = 96), 10 mg/day UPA (n = 98), Placebo (n = 48); Treatment duration: 12–13 weeks; All women received 80 mg/day oral iron</td>
<td>PBAC score &lt;75 was achieved in 5 mg UPA group (91%), 10 mg UPA group (92%), Placebo (19%); Amenorrhoea (PBAC &lt;2) in 10 days: 5 mg UPA group (73%), 10 mg UPA group (82%), Placebo (6%); Median total change in fibroid volume: 5 mg UPA group (−21.2%), 10 mg UPA group (−12.3%), Placebo (+3%); Self-reported pain scores improved compared to placebo: 5 mg UPA group (73%) - Median time 7 days, 10 mg UPA group (89%) - Median time 5 days, Leuprorelin (80%) - Median time 21 days; Adverse effects comparable to placebo</td>
<td>Treatment with ulipristal acetate for 13 weeks effectively controlled excessive bleeding due to uterine fibroids and reduced the size of the fibroids.</td>
</tr>
<tr>
<td>PEARL II</td>
<td>Randomised Double Blind Double Dummy Active Comparator Controlled Noninferiority</td>
<td>Women with symptomatic fibroids; Age: 18–50 years; BMI: 18–40 kg/m²; PBAC score &gt;100 (first 8 days of menstruation); At least one uterine fibroid &gt;3 cm but &lt;10 cm; Fibroid uterus: &lt;16 weeks; Eligible for surgery</td>
<td>Women were randomised in a ratio of 1:1:1 to 5 mg/day UPA + placebo* (n = 97), 10 mg/day UPA + placebo (n = 104), placebo + Leuprorelin 3.75 mg IM monthly (n = 101); Treatment duration: 12–13 weeks; *Placebo in UPA group - IM saline injection</td>
<td>PBAC score &lt;75 was achieved in 5 mg UPA group (90%), 10 mg UPA group (98%), Leuprorelin (89%); Amenorrhoea (PBAC &lt;2) was achieved in 5 mg UPA group (75%) - Median time 7 days, 10 mg UPA group (89%) - Median time 5 days, Leuprorelin (80%) - Median time 21 days; Median total change in fibroid volume: 5 mg UPA group (−36%), 10 mg UPA group (−42%), Leuprorelin (−53%); Hot flushes (moderate to severe): 5 mg UPA group (11%), 10 mg UPA group (10%), Leuprorelin (40%); All three groups had improvements in pain and QoL scores</td>
<td>Treatment with ulipristal acetate for 13 weeks was noninferior to leuprolide acetate in controlling uterine bleeding and was associated with significantly lower risk of hot flushes.</td>
</tr>
</tbody>
</table>

https://doi.org/10.1530/JME-19-0238

© 2020 The authors
Published by Bioscientifica Ltd.
Printed in Great Britain
This work is licensed under a Creative Commons Attribution 4.0 International License.
http://creativecommons.org/licenses/by/4.0/
<table>
<thead>
<tr>
<th>Study Type</th>
<th>Population</th>
<th>Intervention and comparator</th>
<th>Outcomes</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PEARL III</strong>+ Extension 1</td>
<td>Open label - Randomised double blind</td>
<td>Women with symptomatic fibroids; Age: 18–48 years; BMI: 18–40 kg/m²; Regular menstrual cycle; PBAC score &gt;100 (first 8 days of menstruation); At least one uterine fibroid &gt;3 cm but &lt;10 cm; (FSH) &lt;20 IU/L; Fibroid uterus &lt;16 weeks; Eligible for surgery</td>
<td>PEARL III - UPA 10mg/day commenced in the first week of menstruation. Treatment duration 12 weeks (n = 209); Extension 1 - Up to 4 courses of 12 weeks of UPA treatment with drug free intervals, followed by randomised double blind treatment (1:1) to norethisterone acetate (NETA) or placebo for 10 days at the end of each treatment course. (n = 132)*</td>
<td>Amenorrhoea (PBAC &lt;2) was achieved 1st UPA course (79.5%) - Median time 3.5 days 2nd UPA course (88.5%) - Median time 2 days 3rd UPA course (88.2%) - Median time 3 days 4th UPA course (89.7%) - Median time 3 days</td>
</tr>
<tr>
<td><strong>PEARL III</strong>- Extension 1</td>
<td>Open label - Randomised double blind</td>
<td>Women with symptomatic fibroids; Age: 18–48 years; BMI: 18–40 kg/m²; Regular menstrual cycle; PBAC score &gt;100 (first 8 days of menstruation); At least one uterine fibroid &gt;3 cm but &lt;10 cm; (FSH) &lt;20 IU/L; Fibroid uterus &lt;16 weeks; Eligible for surgery</td>
<td>Extension 1 - Up to four additional courses of 12 weeks of UPA treatment with drug free intervals - TOTAL up to 8 courses (n = 64) *</td>
<td>*Participants recruited from the core PEARL III study</td>
</tr>
</tbody>
</table>

*Participants recruited from the core PEARL III study.
### Table 2 Continued.

<table>
<thead>
<tr>
<th>Study</th>
<th>Type</th>
<th>Population</th>
<th>Intervention and comparator</th>
<th>Outcomes</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEARL IV</td>
<td>Randomised Double Blind</td>
<td>Women with symptomatic fibroids; Age: 18–50 years; BMI: 18–40 kg/m²; Regular menstrual cycle; PBAC score &gt;100 (first 8 days of menstruation); At least one uterine fibroid ≥3 cm but ≤12 cm; FSH &lt;20 IU/L; Fibroid uterus ≤16 weeks</td>
<td>Women were randomised in a ratio of 1:1 to 5 mg/day UPA (n = 230) 10 mg/day UPA (n = 221) Treatment duration - Up to four courses of 12 weeks each (84 days) with a drug free interval between courses; until the start of the second menstrual bleed after course completion Women were followed up at 3 months after the fourth treatment course</td>
<td>Amenorrhoea (PBAC &lt;2) was achieved 5 mg UPA group Course 1 - 71.8% Course 2 - 74.1% Course 3 - 73.3% Course 4 - 69.6% All four courses combined - 48.7% 10 mg UPA group Course 1 - 82.6% Course 2 - 82.2% Course 3 - 78.3% Course 4 - 74.5% All 4 courses combined - 60.5% Median change in volume of the 3 largest fibroids at follow up 5 mg UPA group (−65%) 10 mg UPA group (−67.4%) Placebo (−53%) PAEC 5 mg UPA group Baseline - 7.8% Course 2 (16.3%) &amp; Course 4 (16.2%) 3 months post UPA - 9.0% 10 mg UPA group Baseline - 8.4% Course 2 (19.2%) &amp; Course 4 (10.3%) 3 months post UPA - 6.3% Both groups had improvements in pain and QoL scores Headaches and hot flushes were the most commonly reported side effects and occurred in ≤11% of patients, with the frequency of these events decreasing with each successive treatment course.</td>
<td>The study demonstrates the safety and efficacy of repeated intermittent treatment of symptomatic fibroids with UPA.</td>
</tr>
<tr>
<td>VENUS II</td>
<td>Randomised Double Blind</td>
<td>Women with symptomatic fibroids; Age: 18–50 years; Regular menstrual cycle; MBL ≥80 mL measured using the alkali hematin method (first 8 days of menstruation) Minimum one discrete leiomyoma seen by TVUS FS) &lt;20 IU/L Fibroid uterus ≤20 weeks</td>
<td>Women were randomised (n = 432) 5 mg/day UPA 10 mg/day UPA Placebo Randomized to one of six treatment arms in a 1:1:2:1:2:1 ratio, with course 1, course 2 dosing of placebo, ulipristal 5 mg placebo, ulipristal 10 mg; ulipristal 5 mg, 5 mg, placebo; ulipristal 10 mg, placebo; ulipristal 10 mg, placebo Treatment duration - Two courses of 3 months each. There was a two menses drug-free interval in between courses. Women were followed up at 3 months after treatment completion</td>
<td>Amenorrhea was achieved 5 mg UPA group Course 1 - 42% Course 2 - 40.5% 10 mg UPA group Course 1 - 54.8% Course 2 - 57.3% Placebo Course 1 - 0% Course 2 - 8% Improvement from baseline in UFS-QOL revised activities subscale: 5-mg UPA: 48% 10-mg UPA: 57% Placebo: 13%</td>
<td>Consistent with VENUS I and the European studies, both doses of UPA were superior to placebo in the proportion of women achieving amenorrhea and time to amenorrhea.</td>
</tr>
</tbody>
</table>
metalloproteinase (MMP) expression (Xu et al. 2008, Cox et al. 2018).

**UPA and surgery**

There is good quality evidence to support the use of GnRH agonists preoperatively in women with uterine fibroids. The potential advantages include the reduction in fibroid and/or uterine size or volume, improvement in intraoperative blood loss, correction of pre-existing anaemia and the possibility of using more conservative approaches (e.g. vaginal hysterectomy) rather than a midline incision (Lethaby et al. 2002). The major disadvantage of using GnRH analogues for 3–4 months preoperatively is the risk of side effects – predominantly hot flushes and night sweats – due to oestrogen withdrawal. UPA has been compared to GnRH agonists for this purpose and found to have similar efficacy in controlling uterine bleeding and having reduced side effects (10% vs 40%) (Donnez et al. 2012b).

UPA is known to have proapoptotic, antifibrotic and antiproliferative effects on uterine fibroids with myometrial sparing (Gaillard et al. 1985, Xu et al. 2005, Courtoy et al. 2015, Donnez et al. 2018b). UPA is thought to also effect the fibroid pseudocapsule, which in turn is proposed to make surgical planes challenging to identify and subsequently result in difficult fibroid enucleation (Mallick et al. 2019). The pseudocapsule is a fibro-neurovascular structure surrounding the fibroid and separating it from the surrounding myometrium. In performing an ‘intracapsular myomectomy’, the fibroid is dissected from its pseudocapsule by breaking the connective tissue (fibrous) bridges (Tinelli et al. 2012b). An intracapsular myomectomy is recommended as it may subsequently reduce the risk of recurrence, uterine rupture and adhesion formation (Tinelli et al. 2012a). The distortion of the pseudocapsule with UPA use in some cases may increase the difficulty in correctly identifying the surgical planes between the fibroid and its surrounding pseudocapsule, making an intracapsular myomectomy challenging to perform.

Several clinical trials have evaluated the role of UPA prior to myomectomy and have differing outcomes. The MYOMEX trial (ulipristal acetate vs gonadotropin-releasing hormone agonists prior to laparoscopic myomectomy) is a small randomised controlled trial (RCT) (n=55) that compared GnRH analogues (leuprolide acetate 11.25 mg i.m. single dose + oral placebo tablet OD for 12 weeks) vs UPA (5 mg OD for 12 weeks + i.m. saline placebo injection) prior to a laparoscopic myomectomy. Women treated with UPA had higher intraoperative blood loss, longer suturing times for the first fibroid and the myomectomies were perceived to be subjectively more difficult (de Milliano et al. 2020). The MYOMEX trial was underpowered and included a very small number of women. Larger well-designed RCTs are needed before conclusions regarding the use of UPA prior to myomectomy procedures may be drawn. Another recent small (n=10 UPA; n=52 no pre-treatment) retrospective study in the United Kingdom supported the findings of potentially difficult laparoscopic myomectomy with UPA use (Mallick et al. 2019).

However, a recent systematic review which did not include the previously mentioned studies concluded that UPA is a suitable pre-treatment prior to both, hysteroscopic and laparoscopic myomectomies (Ferrero et al. 2019). The results must be interpreted with caution as the studies included are predominantly retrospective or prospective observational studies.
UPA and endometriosis and adenomyosis

At the time of writing this review, we did not identify any RCTs evaluating the role of UPA in managing endometriosis and adenomyosis.

Endometriosis is a condition in which there is the presence of endometrial glands and stroma outside the uterus. It affects one in ten of women of reproductive age and is associated with pelvic pain, HMB and infertility (Eskenazi & Warner 1997, Missmer & Cramer 2003, Bedaiwy et al. 2009). There is conflicting and limited evidence regarding the role of UPA in endometriosis. In animal models (rats with surgically induced endometriosis), UPA was found to induce regression and atrophy of the endometriosis lesions. This was accompanied by upregulation of proapoptotic markers, reduced cell proliferation and inflammatory markers (Huniadi et al. 2013). A case report by Bressler et al. described a significant reduction in endometriosis related refractory chronic pelvic pain, when treated with high dose UPA for 3 months (Bressler et al. 2017). In contrast, Donnez et al. described excellent response to UPA treatment when administered for two 3-month courses with regards to reduction in fibroid size; however, no effect on an ovarian endometrioma, with both conditions co-existing in the same patient (Donnez & Dolmans 2016). The current understanding is that endometriosis lesions occur as superficial endometriosis, deep infiltrating endometriosis (DIE) and ovarian endometriosis (endometriomas). The aetiology of these subtypes is poorly understood and some authors consider them as distinct clinical and pathological entities. There is conflicting evidence on the response of endometriosis to UPA with no clear demarcation between the three subtypes, and therefore, further investigation in the form of well-designed RCTs is necessary.

Bird et al. defined adenomyosis as ‘the benign invasion of the endometrium into the myometrium, producing a diffusely enlarged uterus which microscopically exhibits ectopic, non-neoplastic, endometrial glands and stroma surrounded by the hypertrophic and hyperplastic myometrium’ (Bird et al. 1972). The prevalence of adenomyosis is difficult to ascertain because of a wide variation in diagnostic criteria both with imaging modalities and with histology. It has been estimated that histological confirmation of adenomyosis ranges from 5 to 70% of patients who undergo hysterectomy (Abbott 2017). With improvements in imaging technology, more cases of adenomyosis are now being diagnosed non-invasively both using 2D and 3D pelvic ultrasonography and MRI (Bluhm & Dueholm 2019, Liu et al. 2019).

There is an emerging concept of ‘progesterone resistance’ in the pathogenesis of these hormone-dependent conditions. In a normal cycling human endometrium, levels of the progesterone receptor (PR-A, PR-B; 2 isoforms) increase under the influence of the oestrogen exposure in the follicular phase of the cycle and the levels of the oestrogen receptor (ER) also increase. After ovulation, the levels of ER decline under the influence of rising circulating progesterone concentrations. In women with endometriosis, reduced endometrial PR-A expression compared to eutopic endometrium and an absence of PR-B were reported (Attia et al. 2000). This is likely a contributing mechanism, whereby progesterone does not trigger the expression of the endometrial steroid metabolising enzyme, 17 β hydroxysteroid dehydrogenase type 2 and subsequent metabolism of oestradiol (E2 - potent) to oestrone (E1 - less potent) (Bulun 2009, Bulun et al. 2010, Reis et al. 2013). Conversion of potent E2 to less potent E1, which normally occurs in the secretory phase endometrium, is regarded as a critical protective mechanism against oestrogen-induced growth. Moreover, endometrial expression profiling has documented dysregulation of progesterone-responsive genes in women with endometriosis (Taylor et al. 1999, Aghajanova et al. 2010).

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting women of reproductive age. Women with PCOS present with diverse features which includes those involving the reproductive system, such as, irregular menstrual cycles, hirsutism, infertility and pregnancy complications, along with metabolic features (insulin resistance (IR), metabolic syndrome, prediabetes, type 2 diabetes (DM2) and cardiovascular risk factors (Monash University 2018). Although the concept of altered response to endogenous progesterone (P4), ‘progesterone resistance’ has been addressed in the context of endometriosis, it may be also evident in women with PCOS. A gene microanalysis by Savaris et al. reported that progesterone-regulated genes, including mitogen-inducible gene 6 (MIG6), leukemia inhibitory factor (LIF), GRB2-associated binding protein 1 (GAB1), S100P and claudin-4, were significantly lower in the endometrium of women with PCOS, whereas cell proliferation genes, such as Anillin and cyclin B1, were up-regulated. These data lend support to the concept of progesterone resistance (Savaris et al. 2011). The altered expression of the isoforms of the progesterone receptor (PR-A, PR-B) and the downstream signalling pathways has also been proposed as a mechanism for progesterone resistance in women with PCOS; however, further discussion is beyond the scope of this review (Li et al. 2014).
Mifepristone (RU-486)

The first SPRM, RU486 (mifepristone), was discovered in the 1980s, during the quest for discovery for anti-glucocorticoid drugs (Moguilewsky & Philibert 1984) by the French pharmaceutical company Roussel-Uclaf. Mifepristone was synthesised by Georges Teutsch and is also referred as to RU-486, that is, RU-38486, the 38,486th compound synthesised by Roussel-Uclaf from 1949 to 1980, which has been shortened to RU-486. The drug was subsequently trialled for pregnancy interruption after its antiprogestin properties were investigated by Étienne-Émile Baulieu, a French endocrinologist and biochemist. Baulieu is often referred to as the ‘father’ of the abortion pill (Baulieu & Rosenblum 1991).

The chemical structure of mifepristone is shown in Fig. 4. It is a synthetic estrane steroid and its chemical name is 11β-(4-(dimethylamino) phenyl)-17α-(1-propynyl) estra-4,9-dien-17β-ol-3-one.

SPRMs may have mixed progestational agonist and antagonist activity, which can be assessed by the McPhail test conducted in immature female rabbits. The test consists of administration of oestradiol benzoate (day 1 to 6), followed by administration of the study drug (e.g. SPRM; day 7–12). Controls receive either the vehicle or oestradiol benzoate only. The rabbits are killed on day 15, and the mid portions of the uteri are then analysed histologically to assess changes in the endometrium, which are subsequently scored. Using this test, mifepristone is classed as a ‘pure’ antagonist (McPhail 1934, Elger et al. 2000, Chwalisz et al. 2005); however, it must be noted that in the absence of progesterone, mifepristone has a partial agonist effect. The test is now rarely used (Fig. 5).

In addition to its effects on PR, mifepristone is also a potent anti-glucocorticoid and a weak antiandrogen. It has a significantly higher affinity to the glucocorticoid receptor (GR) as compared to the endogenous corticosteroid cortisol (ten times) or dexamethasone (three times) (Philibert et al. 1985, Baulieu 2013). The anti-glucocorticoid actions are both centrally (ACTH feedback loop) and peripherally (via GR) mediated at doses >400 mg/day, administered as a single dose (Bertagna et al. 1984, Gaillard et al. 1985). Mifepristone is reported to be devoid of oestrogenic, anti-oestrogenic, mineralocorticoid and anti-mineralocorticoid properties.

Mifepristone and pregnancy interruption

Mifepristone is the only SPRM that can interrupt pregnancy in several species, including humans, and is licensed for this purpose in several countries. The combination of mifepristone (usually 200 mg) and misoprostol, a prostaglandin analogue, is widely used for medical abortion in the first trimester (Cameron et al. 1986, Rodger et al. 1989, Raymond et al. 2013). Most focus has been on offering medical abortions to women ≤63 days of gestation, as these may be undertaken at home with great efficacy, safety and acceptability to women. This may be offered using a combination of 200 mg of oral mifepristone and vaginal or buccal misoprostol (Schaff et al. 2000, Chen & Creinin 2015).

More recent evidence also supports the role of using mifepristone-misoprostol for medical abortion from 64 to
70 days with a low rate of serious adverse events and high efficacy, also suitable in a ‘home setting’ (Hsia et al. 2019).

In the United Kingdom, the Royal College of Obstetricians and Gynaecologists (RCOG) suggests that medical abortion regimens using 200 mg oral mifepristone and misoprostol are effective and appropriate at any gestation, although as gestation increases, these would have to be undertaken in a medical facility (Royal College of Obstetricians and Gynaecologists 2011, National Institute for Health and Care Excellence 2019).

**Mifepristone and fibroids**

The first clinical human trial ($n=10$) to determine the effects of mifepristone in women with fibroids was published in 1993 and revealed that 50 mg/day administered over a 3-month period could shrink fibroids and was well tolerated (Murphy et al. 1993). The same team subsequently demonstrated that 25 mg/day dosing was optimal for this purpose and induced ovarian acyclicity (Murphy et al. 1995).

Since then, several studies have been published demonstrating the benefits of using mifepristone in women with fibroids. A recent meta-analysis (11 RCTs and 780 women) concluded that mifepristone significantly reduces uterine and fibroid (leiomyoma) volume and improves associated symptoms (HMB, dysmenorrhoea, pelvic pain, pressure and anaemia). The authors recommend 2.5 mg/day for 3 or 6 months as the optimum clinical treatment for uterine fibroids (leiomyoma). There is insufficient evidence to link its use to endometrial hyperplasia; however, monitoring of endometrial health should be undertaken (Shen et al. 2013).

In contrast, Cochrane (three RCTs and 112 women) concluded that mifepristone reduced HMB and improved fibroid-specific quality of life. However, it was not found to reduce fibroid volume and was associated with an increased risk of abnormalities in endometrial histology (Tristan et al. 2012). The endometrial changes are indistinguishable from PAEC induced by other SPRMs (Fiscella et al. 2011).

**Mifepristone and Emergency Contraception**

WHO defines ‘Emergency Contraception’ as methods of contraception that may be used to prevent pregnancy after sexual intercourse. The mechanism of action of mifepristone, however, depends upon its timing of administration in the menstrual cycle. When administered in the follicular phase, it prevents the LH surge and interrupts/delays ovulation (Spitz et al. 1996). If administered immediately at or after ovulation, it may block tubal motility and or blastocyst attachment or nidation as seen in vitro, that is, administration is contragestive rather than contraceptive (Lalitkumar et al. 2007).

Evidence suggests that mifepristone in a dose of 10 mg used up to 120 h after UPSI is an effective emergency contraceptive (Piaggio et al. 2003a). A Cochrane review has also supported the use of mifepristone as an emergency contraceptive (Cheng et al. 2008).

Higher doses are associated with a delay in menstruation (with added stress and anxiety of potential pregnancy), vaginal bleeds within 5 days of oral mifepristone and fatigue, and hence, the preference for the use of lower doses (Task Force on Postovulatory Methods of Fertility Regulation 1999).

A meta analysis has evaluated the administration of mifepristone at doses between 5 mg and 600 mg for the purpose of emergency contraception. The pregnancy rate increases by a factor of 1.6 when the dose of 10 mg is used instead of 25 mg. In terms of the number of women needed to treat, however, using 10 mg in the place of 25 mg implies having one extra pregnancy every 146 women requesting emergency contraception (Piaggio et al. 2003b).

**Mifepristone and long-term contraception**

The first human clinical trial ($n=21$) using mifepristone as a long-term contraceptive utilised a 200 mg single dose 48 h after an LH surge, determined by using urinary LH kits, with a treatment duration between 1 and 12 months. The endometrial effects were considered adequate to prevent pregnancy. The only major side effect was vaginal bleeding noted in a third of women, 2–3 days after treatment (Gemzell-Danielsson et al. 1993).

Evidence also shows that mifepristone at doses 2–5 mg/day (up to 120 days) has the potential to suppress the LH surge and subsequently ovulation, providing contraception and inducing amenorrhoea (Brown et al. 2002). A small study compared the daily administration of mifepristone 5 mg/day ($n=73$) vs levonorgestrel 30 µg/day (progesterone only pill; $n=23$) for 24 weeks. Mifepristone was found to be an effective contraceptive with improved bleeding patterns; however, benign endometrial changes (now described as PAEC) were noted with 6 months of use (Lakha et al. 2007). Mifepristone has also been evaluated as a ‘once-monthly’ pill; however, the results as a reliable contraceptive have been disappointing (Narvekar et al. 2006).
Mifepristone and endometriosis

The first human clinical studies using the drug for women diagnosed with endometriosis showed promising results. The drug was used in a dose of 100 mg/day for 3 months (Kettel et al. 1991) or 50 mg/day for 6 months (Kettel et al. 1996). In the higher dose, short-term use group, improvement in endometriosis symptoms were noted, but no regression of endometriotic lesions was seen at post-treatment laparoscopy. In addition, evidence of hypercortisolism was noted. In the subsequent study, using a lower dose for a long duration, in addition to symptomatic improvement and regression of endometriotic lesions, a clear dissociation from the anti-glucocorticoid activity was noted.

Cochrane currently suggests that mifepristone improves endometriosis-associated dysmenorrhoea and potentially dyspareunia. Amenorrhoea is a common association and is classed as a ‘side effect’, although, lack of menstruation may be clearly beneficial in women with endometriosis-associated HMB. Doses <2.5 mg/day are less likely to be effective; however, based on the available evidence, clear conclusions on dosage cannot be made (Fu et al. 2017).

Mifepristone and use for non-gynaecological indications

Although a full review of the non-gynaecological benefits of mifepristone is beyond the scope of this article, it has been explored and used in the clinical context for the indications discussed in the subsequent section.

Mifepristone has been explored as an anti-glucocorticoid drug. This may particularly be of value in the medical treatment of Cushing’s disease; mifepristone is considered as an adjuvant drug in this regard (Carmichael & Fleseriu 2013). The drug also shows potential for treating neuropsychiatric disorders, mood disorders and Alzheimer’s disease (DeBattista & Belanoff 2006). Mifepristone has also been trialled in the management of inoperable meningiomas (Haak et al. 1990, Matsuda et al. 1994).

For its antiprogesterone properties, mifepristone has been evaluated in the management of breast cancers (Romieu et al. 1987, Klijn et al. 1989). Treatment with RU486 (mifepristone) has been shown to prevent mammary tumorigenesis in Brca1/Trp53-deficient mice (Poole et al. 2006). The potential role of SPRMs in the prevention of breast cancer has been previously proposed (Bouchard et al. 2011).

Vilaprisan

Vilaprisan (BAY 1002670) is a more recent, potent, orally active SPRM. Vilaprisan was developed by and is the property of Bayer AG, Berlin, Germany. It is a 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-diene-11-aryl derivative. Vilaprisan can weakly bind to the glucocorticoid receptor and androgen receptor with no effect on the oestrogen receptor (Wagenfeld et al. 2013, Möller et al. 2018). Its chemical structure is shown in Fig. 6.

Clinical trials

The currently available information for vilaprisan is generated from human clinical phase I and II trials in women with HMB and fibroids (Bradley et al. 2016, Schütt et al. 2016, 2018, Schultze-Mosgau et al. 2017, 2018). The results of the first trials comparing vilaprisan vs ulipristal acetate vs placebo in a randomised, double-blind, parallel-group fashion (ASTEROID 2 study) have not been published at the time of writing this paper. The findings from these trials are listed in Table 3.

Vilaprisan has been undergoing clinical trials for management of HMB with uterine fibroids (ASTEROID 5; NCT Identifier: 03240523, ASTEROID 6; NCT Identifier: 03699176 and ASTEROID 7; NCT Identifier: 03699176) and a phase 2B randomised placebo-controlled trial in managing women with symptomatic endometriosis (NCT Identifier: 03573336; VILLENDO Study). At the time of writing this article, all vilaprisan trials were on hold due to new safety findings in long-term toxicology study in rodents (Bayer 2018, Burger 2018).
Table 3  Summary of key findings of phase I and II clinical trials utilising vilaprisan.

| Phase I clinical trials (Schütt et al. 2016, 2018) Vilaprisan 0.5–5 mg/day for 12 weeks |
|---|---|
| 1. Maximal non-bleeding rates achieved at dose of 2 mg or higher per day. |
| 2. Doses >0.5 mg/day are associated with a decrease in FSH and LH. |
| 3. Follicular growth-mid-follicular oestradiol levels maintained. |
| 4. Ovulation inhibited on >80% of participants at doses ≥1 mg/day. |
| 5. Return of menstruation in ≤52 days after discontinuation. |
| 6. No serious adverse events. A non-dose dependent transient rise in liver transaminases seen during treatment with vilaprisan which returned to baseline. |
| 7. PAEC present in 10% of women pre-treatment and with 100% frequency in women on 5 mg/day (dose dependent). At doses of 1 mg/day, PAEC was observed in 70–90% of women. Regression was noted in majority of women at first bleed post treatment with regression in all participants at 4–6 months. |

| Phase II clinical trial (Bradley et al. 2016) Vilaprisan 0.5–4 mg/day for 12 weeks |
|---|---|
| 1. Amenorrhoea (MBL <2 ml/28 days by alkali hematin) seen in 87–92% of participants at doses of 1 mg/day or higher. |
| 2. Median time of amenorrhoea ~3 days. |
| 3. Dose dependent reduction in fibroid size; up to 40% at 4 mg dose. |
| 4. Improvements in HRQoL. |
| 5. No serious adverse events. |
| 6. PAEC seen in up to 40% of women on completing treatment with vilaprisan. Complete regression of PAEC to baseline levels was observed during the follow up period (24 weeks). |

Conclusion

SPRMs have been in development since the 1980s, and yet a perfect SPRM does not exist. The class of compounds do have some common effects, including suppression of the LH surge, anovulation, amenorrhoea and benign endometrial changes or PAEC. Some SPRMs have clear indications and therapeutic benefits, for example, mifepristone for pregnancy interruption and ulipristal acetate for emergency contraception and management of fibroid related HMB.

There still appears to be a great void in what SPRMs could achieve in terms of their therapeutic potential. There are few well-conducted RCTs which examine the role of SPRMs in endometriosis, adenomyosis or hormonally mediated chronic pain syndromes. For AUB alone, which is common (affecting one in four women of reproductive age) and debilitating, the role of SPRMs yet remains to be determined. The UCON study (Ulipristal vs Coil for the Management of Heavy Menstrual Bleeding; EudraCT: 2014-003408-65) once completed may provide valuable insights as to the utility of SPRM (UPA) administration in women with and without fibroids. SPRMs may also offer the potential of long-term oestrogen free contraception with less unscheduled bleeding – the side effect occurring in 20% of users of progestin-only methods of contraception (Lethaby et al. 2015). Optimal routes for administration for contraceptive indications will also require evaluation.

The attractiveness of SPRMs lies in the fact that they may be orally administered but have the potential for local drug delivery, that is, via intrauterine or vaginal routes. They have the advantage of maintaining peripheral mid-follicular oestradiol levels, avoiding hypo-oestrogenic side effects. From the perspective of the clinician, this means a class of drugs which may help in the medical management of common gynaecological pathologies without the side-effect profile of current standard medical treatments. From the academic perspective, very little is known about the endometrial mechanisms underpinning the development of PAEC and the long-term implications on the endometrial molecular signature.

These are reasons to further pursue research, development and undertake well-conducted clinical trials involving SPRMs with the ultimate goal of improving women’s health and their quality of life.

Declaration of interest

H O D C has clinical research support for laboratory consumables and staff from Bayer AG and provides consultancy advice (but with no personal remuneration) for Bayer AG, PregLem SA, Gedeon Richter, Vifor Pharma UK Ltd, AbbVie Inc. and Myovant Sciences GmbH. H O D C receives royalties from UpToDate for the article on abnormal uterine bleeding. R R C has received support from Bayer AG as a clinical research fellow.

Funding

This work did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Acknowledgements

The authors thank Sheila Milne for her assistance with manuscript preparation and Prof Alistair Williams for his review of the manuscript. The authors acknowledge the following funding from the Medical Research Council (G9523250; MR/J003611/1; MR/N022556/1) and Tenovus Scotland for support of studies from which data derived have been described in this review.

References


Cheng L, Che Y & Gulmezoglu AM 2012 Interventions for emergency contraception. *Cochrane Database of Systematic Reviews* CD001324. (https://doi.org/10.1002/14651858.CD001324.pub4)


McEwan IJ 2009 Nuclear receptors: one big family. Methods in Molecular Biology 505 3–18. (https://doi.org/10.1007/978-1-60327-575-0_1)


National Institute for Health and Care Excellence 2019 Abortion care (NG140) [Online], (available at: https://www.nice.org.uk/guidance/ng140/). Accessed.


pseudocapsule. *Journal of the Society of Laparoendoscopic Surgeons* **16** 119–129. [https://doi.org/10.4293/108680812X13291597716302](https://doi.org/10.4293/108680812X13291597716302)


Received in final form 12 January 2020
Accepted 30 January 2020
Accepted Manuscript published online 30 January 2020

Williams AR, Bergeron C, Barlow DH & Ferenczy A 2012 Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. *International Journal of Gynecological Pathology* **31** 556–569. [https://doi.org/10.1097/PGPB.0b013e318251035b](https://doi.org/10.1097/PGPB.0b013e318251035b)

